Posted by Michael Wonder on 30 Aug 2022
Quizartinib supplemental new drug application submitted in Japan for patients with newly diagnosed FLT3-ITD positive acute myeloid leukaemia
30 August 2022 - Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
Daiichi Sankyo today announced that it has submitted a supplemental new drug application to Japan’s MHLW for quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy and as continuation monotherapy for the treatment of adult patients in Japan with newly diagnosed FLT3-ITD positive acute myeloid leukaemia.
